Slides on Key Decisions in HIV Care: Managing ART With Opportunistic Infections

Learn key considerations for the initiation and management of ART in the setting of opportunistic infections. Topics include current data and recommendations for patients with pneumocystis pneumonia, Kaposi’s sarcoma, cytomegalovirus, and cryptococcal meningitis.
Cristina Mussini, MD
William R. Short, MD, MPH, AAHIVS
Format: Microsoft PowerPoint (.ppt)
File Size: 1.06 MB
Released: March 21, 2022

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 30, 2022

Dr Milosz Parczewski, discusses the latest data on LA PrEP, HCV treatment in PWH, and treatments for MDR TB presented at CROI 2022 and their relevance to the CEE, from Clinical Care Options (CCO).

Milosz Parczewski, MD, PhD Released: March 11, 2022

Expert insight on key ART considerations for people with HIV requiring treatment for drug-susceptible tuberculosis (TB), from Clinical Care Options (CCO)

Daria Podlekareva, MD, PhD Released: March 7, 2022

Slides from Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings